Merck KGaA (MRK) Earnings Call Transcript & Summary
March 5, 2020
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and thank you for joining the Merck investor and analyst call covering the fourth quarter of 2019. I'd like to remind everyone that this session is being held in listen-only mode for all attendees. At this point, I'll turn things over to Constantin Fest, our Head of Investor Relations, who will guide you through today's conference. Please go ahead, sir.
Constantin Fest
executiveThanks, Kevin. Yes. I’d like to give a warm welcome to everyone from my end to Merck’s earnings and results call for full year 2019. I’m Constantin Fest, Head of Investor Relations at Merck.
Stefan Oschmann
executiveThanks, Constantin. And welcome, everyone, to our call covering full year results. I'll jump straight to Slide number 5 in the deck, beginning with the highlights. For us, 2019 proved a successful year. Strong operational performance came through across all three of our business sectors. Our strategic agenda moved forward significantly, and our guidance was delivered on. Health care had a very good year overall, with modest growth in the base business and powerful contributions from new products, especially Mavenclad. At the same time, we pushed our pipeline forward considerably and managed our cost base with rigor. Life Science once again posted very strong above-market growth, paired with further margin expansion. Cost control stayed in place, and we strengthened our position further through innovations and considerable investments across the portfolio. Performance Materials encountered difficult market conditions in most of its businesses last year, yet we made meaningful progress in our bright future transformation program and successfully closed the landmark acquisition of Versum. That said, we look toward 2020 with optimism. And while we will comment on our guidance in more detail later, let me keep it simple here by repeating what we also told you at our latest Capital Markets Day.
Stefan Oschmann
executiveMerck represents reliable profit expansion with elevated margins and a low-risk character when markets are turbulent. Now let's go to Slide 6, which summarizes what we might call our headline commitments for the past year. And as you can see, every one of those was met. We take particular pride in the fact that, even with the difficult market situation in Performance Materials, we managed to raise group sales organically by more than 5%, which aligns with our goal of achieving profit growth at a still quicker pace. Turning now to the following slide, we see the regional breakdown of the €16 billion in sales that we produced last year. The growth was broad, with positive organic progress across every region. Asia accounted for 35% of sales, whereas Europe represents roughly 30% and North America roughly 25%. Moving to Slide 8. As this morning's release showed, we will put a dividend of €1.3 per share to the AGM on April 24. That amounts to a 4% rise versus the prior year and a payout ratio of 23.4% of EPS pre, consistent with our dividend policy.
Marcus Kuhnert
executiveThanks, Stefan, and hello from me as well. I'm on Slide 14 now, which gives an overview of our key figures for 2019.
Kai Beckmann
executiveThanks, Marcus. And a warm welcome from me as well, everyone. I'm now on Slide '19. Just so you're aware, market conditions were pretty tough for most of the business in Performance Materials through 2019. And as expected, Q4 was no exception. Organically, sales fell 15% and EBITDA pre was down 13% — or, viewed differently, down 15% organically while also adjusted for positive IFRS 16 effects. Similar to Q3, the key factor behind that organic sales performance was a double-digit drop in solutions, and robust OLED growth was more than outweighed by substantial declines in Liquid Crystals against tough prior-year comparables. Sales in Semiconductor Solutions declined 5% organically, yet reassuringly came in well above a soft end market. Surface Solutions, meanwhile, was down somewhat less, mainly because of continued weakness in automotive. On a deposit basis, sales and EBITDA pre both jumped 27%, partly from FX tailwinds and, most importantly of course, sizable first-time consolidation benefits from Versum. As you'll have noticed, the portfolio effect on sales and EBITDA pre in Q4 falls a bit short of the contribution from Versum we guided after the early-October closing.
Kai Beckmann
executiveBut bear in mind that this portfolio effect covers not just Versum — intermolecular is in there too, and that business is producing only small sales while still running up costs. Phasing effects were another headwind as well. The truth is that Versum's underlying performance remains solid, and integration is progressing nicely. Still, before I go deeper on integration and the synergies we have planned, let me step back for a moment and remind everyone of the larger picture. On Slide 20 you can see that, with Versum now part of the company, Semiconductor Solutions' contribution has about doubled, reaching 50% of sales in Q4, with Display Solutions next at 36% and Surface Solutions at 14%. So we have achieved meaningful progress on our strategic agenda of transforming Performance Materials into a top electronics materials player with exposure to appealing end-market trends tied to digitization. As we laid out previously, we do expect Semiconductor Solutions to deliver sales growth in the mid to high single digit over the medium term, backed by secular growth trends such as Artificial Intelligence, 5G and the Internet of Things. Versum and intermolecular let us close key gaps along the value chain, and we believe we are strongly positioned to take full advantage of these promising trends.
Kai Beckmann
executiveIn addition, the conversations we're having with customers right now, along with a number of industry data points, indicate that end markets are near the bottom of a cyclical trough and ought to get back to growth before long. In the meantime, we'll keep managing our Liquid Crystal business rigorously for cash. And as Stefan mentioned earlier, we're very pleased with how our future program is progressing. To give you an example, we shut down our site in Chilworth, U.K. in September, and we're continuing to push an efficient reallocation of resources toward the pockets of growth inside Display Solutions. OLED is one case in point, while we've further sharpened our focus in Surface Solutions. So, taking it all together, we're confident that we'll achieve the targeted turnaround of Performance Materials in 2020 and further leverage our investments to deliver attractive sales and earnings growth in the outer years. With that, let me turn to Slide 21 and give you an update on the Versum integration. All in all, the Versum integration is going smoothly, and we're making progress toward launching the combined organization on June 1st. We've already announced nearly all managers down to the third leadership level and are now working on the teams below that. Synergies are on track as well, and we confirm our target of €75 million in cost synergies from 2020 onwards, with integration cost of €125 million spread across 2020 and 2021.
Kai Beckmann
executiveWe expect cost synergies to build in a linear way each quarter, drawn from three primary sources: Business Optimization, Procurement and Supply Chain, and Administrative Functions. Our teams are putting in serious effort to pinpoint and capture the relevant levers as quickly as they can, and naturally, without causing disruption to the business. Regarding supply chain, we announced our first site closure not long ago. Administrative work is also progressing very smoothly, and the cultural fit has been genuinely encouraging. So I'm certain there will be more questions on this later, but at this point, let me turn things back over to Marcus.
Marcus Kuhnert
executiveThanks, Kai. Moving to Slide 22, I'll make a few comments about the balance sheet. Our balance sheet grew relative to the end of 2018, and that mostly reflects the Versum acquisition, which closed in October. As a result, at the close of 2019, our equity ratio is 41%, while net debt-to-EBITDA sits at 2.8 times. Given that, and as we already noted on the Q3 earnings call, the focus over the next 2 years will be deleveraging. In November, we also committed to giving you an update on the Versum-related PPAs, or purchase price allocation effect. So please follow me to Slide 23, where there's an overview of that. The largest balance sheet impacts from identified intangible assets and goodwill each come to approximately €3 billion. The single biggest component of intangible assets relates to Versum's customer relations, totaling €2.3 billion. Every intangible asset other than goodwill gets amortized across its defined useful life. That means, first, we take the conservative approach to the balance sheet, as you're familiar with from our earlier acquisitions. Second, that incremental €3 billion in intangible assets will produce additional amortization of between €230 million and €250 million per annum going forward.
Marcus Kuhnert
executiveFinally, turning briefly to cash flow, which you can see on Slide number 24. Operating cash flow came in solid at €690 million, whereas investing cash flow largely reflects the Versum acquisition. That said, I'll now return the floor to Stefan for the outlook.
Stefan Oschmann
executiveThanks, Marcus. Moving to Slide 26. As I said earlier, we are approaching 2020 with optimism—a good deal of optimism, in fact. Before I get into the specifics of our guidance, though, I want to spend a moment on the evolving Coronavirus situation. Above all, our top priority is safeguarding our employees and the well-being of their families. We are also placing heavy emphasis on supply, security, and business continuity. We provide technologies that support the development and production of vaccines and treatments. And consistent with our 352-year history of responsibility toward the communities where we operate, we are backing internal China's fight against COVID-19 through numerous donations and efforts, life science products among them. How much economic damage this crisis will cause, both within China and beyond it, is highly uncertain—and so are the effects on our business. That said, we are confident we will handle the situation well and that our diversified setup will prove its worth yet again. Right now we are working through various scenarios. We are examining historical models from other crises, more or less applicable. We have concluded that these crises—whether precision-related or disease threats—have an industry-specific impact that we must factor in, and we are now sharing with you a scenario we put together in mid-February, on Slide 26.
Stefan Oschmann
executiveIn this scenario, we're assuming COVID-19 peaks during Q1, lets up in Q2, and that things are more or less back to normal during the second half of the year. All told, this scenario works out to roughly a 1% drag on our full year sales, coming mostly from China and mostly hitting in Q1. And that's already baked into our qualitative outlook for 2020. That said, if the impact turns out to be significantly more pronounced, or if the crisis leads to a global recession, please keep in mind that this guidance would have to be adjusted, and we can probably get into more detail on that during the discussion. With that, let's turn to Slide 27 for guidance. We're expecting solid organic sales growth in 2020, combined with positive portfolio effects from Versum in the mid single digit percentages, and partly offset by exchange headwinds in a range of zero to minus 3%. For EBITDA pre, we're guiding to strong organic growth, while Versum and FX should have the same relative impact as per sales. Further on exchange, please note that our forecast for the euro-U.S. dollar rate for 2020 is a range of 1.11 to 1.16, while we've hedged about 50% of our exposure at a euro-dollar rate of 1.18 — both of which are the main drivers behind the anticipated exchange headwinds.
Stefan Oschmann
executiveMoving to Slide 28, we'll walk you through our summary of the main earnings drivers and underlying assumptions for 2020. Honestly, there shouldn't be much here that surprises you, so just a few extra remarks. We're also aligned with the business sector guidance shown on our previous slide. Regarding Healthcare, we've said many times that we intend to be more balanced on other operating income, and our 2020 guidance reflects that. Specifically, as Marcus noted earlier, we presently anticipate a low triple-digit million amount from GSK and as much as a mid double-digit euro million amount from active portfolio management. On Life Science, again as Marcus mentioned, we're holding to our ambition of margin expansion within a 20 to 30 basis point range for the current year. But we'd rather not be too explicit about outer years. For Performance Materials, please keep in mind that our guidance assumes Semiconductor Solutions gets back to growth in the current year. We feel confident about that, drawing on conversations with customers and emerging industry data points. Now let's turn to your questions.
Constantin Fest
executiveKevin, we’ll take the first question from you.
Operator
operatorThanks. Our opening question is from Matt Weston at Credit Suisse.
Matthew Weston
analystThanks a lot, and good morning or good afternoon. I’ve got three questions, if I may. First, just briefly on Corona: you were kind enough to give us the revenue impact. Could you give us some indication of what margin we should assume that falls through to the bottom line at? Is it at the group margin, or is it at a much higher level, given the operational leverage in the business? I’m also mindful that in mid-February we haven’t really seen the outbreak affect Korea, which is a very large market for semiconductor manufacturing. So can you just confirm whether or not you expect that to have an impact going forward? Second, a question on guidance. I’m aware that you use solid as your adjective for sales growth but strong for EBITDA, which essentially suggests meaningful margin expansion at the business. You’ve given us very clear levers for Healthcare. You’ve said it’s 20 to 30 basis points within Life Science, which suggests very meaningful organic margin expansion at Performance Materials. I know you’ve just mentioned that you assume semiconductor pickup. If you could just give us some idea of levers, that would be very helpful. And then finally, Mavenclad in the U.S.
Matthew Weston
analystIt looks like prescription trends are leveling off. Could you help us understand whether we're overlooking something there, or whether the IQVIA data simply isn't picking up that trend — and what makes you confident that growth will keep going?
Stefan Oschmann
executiveThanks, Matt. My suggestion is that Marcus take the guidance question first, and after that I’ll get into what you asked about Corona and Mavenclad.
Marcus Kuhnert
executiveOkay, yes—hi, Matthew. Thanks for asking about guidance. First, let me restate something, since we’ve already had a few questions this morning about our qualitative guidance: as you’re aware, it is Merck corporate policy that on the March conference call we give qualitative guidance for the year, and that guidance becomes quantitative 2 months from now, when we publish Q1 figures in May; at that point we provide numeric corridors in the way we normally do. So the wording does indeed imply that we anticipate a further margin increase in 2020 versus 2019. You’ve read that exactly right. We therefore expect EBITDA to rise faster than sales in the current year, 2020. If we pull back a bit to look at the 3 business sectors: in Healthcare, I think it’s fair to assume we expect a slight margin improvement in 2020. In Life Science, we’re very explicit about our expectation of margin expansion of 20 to 30 basis points. And finally, in Performance Materials, as we’ve already said, we expect a recovery in Semiconductor Solutions, and we expect the downward trend in Liquid Crystals to continue. We’re in display—for display materials overall.
Marcus Kuhnert
executiveWe also anticipate that Surface Solutions will do a bit better than it did in 2019. And beyond that, Versum will of course give us some support—it will operate largely on a standalone basis and be slightly accretive to performance Materials on the margin plus side. As you've seen, we additionally forecast that €20 million in cost synergies will have been realized by the close of this year. So putting all of that together, yes, our margin should rise in 2020 compared with '19.
Stefan Oschmann
executiveYes, I'll begin with Mavenclad. I take it your question was about U.S. market share, and I'd humbly point you to slide 40, where what we're actually seeing is rather the reverse of a market share. Instead, we're seeing ongoing growth in the high efficacy dynamic market share as well as in the oral class share. We're also seeing patient access continue to increase. We had some notable access wins recently and major plans, among them Prime Therapeutics, United and others, also covering Mavenclad. Now outside the U.S., our strong launch progress continues. As you know, we are approved in 75 countries at this point. On perception, in our tracking we hold leading perceptions in the oral class in key markets such as Germany, the U.K., Italy and Spain. And growth ex-U.S. will be driven by continued demand acceleration plus the full year impact of market access wins in 2019. I hope that answers your question. When it comes to Corona on margin, I wouldn't expect any radically different picture from the revenue situation. I assume you can appreciate that at this stage we cannot share guidance with you on the Corona impact on margin per week and country or so.
Stefan Oschmann
executiveThings are moving quickly. Right — that scenario we outlined for mid-February doesn’t factor in any effect from Korea up to now. When you look at what leading epidemiologists are projecting, it’s fairly clear that a lot of them believe this epidemiological trajectory implies that essentially 60%, 70%, 80% of the population will become infected at some point, and that managing an epidemic really comes down to postponing the onset so that the respective healthcare systems don’t get overwhelmed. Quite a few people anticipate some easing of the situation as ambient temperatures go up, and we’ve observed that in China — in certain warmer regions, the impact has been much smaller, and lately Guangdong province has been reporting a very, very stable situation. So predicting is basically impossible. If you consider the effect that other epidemics or epidemic threats have had on different industries across various models, or on the — I know it isn’t 100% comparable, but to some degree, the financial crisis produced a similar psychological effect. And as I mentioned earlier, it’s highly industry specific. We aren’t a cruise line. We aren’t an airline. Obviously, we’re a company that makes biopharmaceutical drugs.
Stefan Oschmann
executiveWe make lab equipment and lab reagents, and we're active in biologics manufacturing. So clearly there are both negative and positive factors at play there. If I look at Performance Materials and rank which of our businesses might be affected, I'd put it this way: the one likely to be affected the least is Semicon, then Display comes next, and after that comes Surface Solutions.
Operator
operatorMark Purcell from Morgan Stanley has our next question.
Mark Purcell
analystYes, thanks so much for taking my questions. There are three, please. First, China sales in 2019 were €2.3 billion — could you give us a rough idea of how that splits across divisions? And then within Healthcare, you specifically pointed to fertility and oncology as the areas hit hardest — fertility, I suppose, being a procedure that people wait for, and oncology too. That's more difficult to understand, I guess, but could you help us get a sense of what proportion of Healthcare sales comes from fertility and oncology, with fertility being the one I think was most impacted? And then your guidance, stepping back, implies roughly a 7% revenue impact in China from COVID-19. Is that based on in-channel demand you saw through to the middle of February? Or does it include any impact so far on supply on your side of the business? And secondly, on TGF-beta trap. Could you help us understand where you are in recruiting the initial 300 patients in the lung 037 trial versus pembrolizumab? And when do you expect that section of the trial to complete? I mean, at this stage, will you keep recruiting patients beyond the 300, to say 500-plus, to make it a pivotal trial?
Mark Purcell
analystAnd will that happen regardless of the interim analysis? If expanding the study requires an interim analysis, what would you estimate at this point as to when that interim analysis might occur? So that makes two questions. Thank you very much.
Stefan Oschmann
executiveMark, I'll begin with your first question about China—your overall sales estimate is fairly accurate. From that total, you can figure roughly 50% comes from Healthcare. The remainder is split relatively evenly between Life Science and Performance Materials.
Marcus Kuhnert
executiveI'll be handling your questions from here. As a general rule, we don't disclose franchise figures for individual countries. The dynamics in fertility and oncology are pretty straightforward. Fertility is heavily dependent on a certain level of consumer confidence — when couples and families feel worried about what lies ahead, they pursue less fertility treatment. On the oncology side, obviously, cancer cases themselves aren't affected by the COVID-19 crisis. Still, experience indicates that diagnosis rates drop in these circumstances, which ought to be a temporary phenomenon. On your question about bintrafusp alfa, that trial remains on schedule, with estimated primary completion expected near the close of '21. During 2020, only a small group reviews the data, and nothing will be shared internally or externally. Keep in mind that preserving data integrity and trial integrity truly matters. On the basis of the data, a decision on whether to expand the trial's size could be made, and obviously we — as does our partner — want enough patients to ensure sufficient power for a benefit that holds up. It is already a pivotal study at this point.
Mark Purcell
analystThanks a lot. That's really helpful. And then finally, regarding the China piece of the supply chain question, have you noticed much of an effect so far on your supply chain within all three of your businesses?
Stefan Oschmann
executiveUp to now, we have not observed any effect, any meaningful effect. We're examining every single line item extremely carefully. It's encouraging to see how diligently our staff are performing under these circumstances, and how tight the ties are with both our suppliers and our customers. We're tracking that extremely attentively. On the whole, there's considerable worry in political circles, and so on, regarding shortages of drugs. Based on what I understand, I believe the reliance on API sourced from China is somewhat overstated. Keep in mind that we — within the company, we have numerous biologics in our pipeline, and for all of those biologics the API is manufactured in Europe, either in Switzerland or in Spain. We also produce API in Europe for a number of our oral products. The problem with supply of medicines in China could involve excipients — to my knowledge, the vast majority of pharmaceutical excipients are manufactured in China, and that will be a longer-term subject.
Mark Purcell
analystThat's wonderful. Thanks a lot. I appreciate it.
Operator
operatorRichard Vosser from JPMorgan has our next question.
Richard Vosser
analystHello, and thank you for taking my questions. There are a couple of things, if I may. First, could you bring us up to date on how Mavenclad sales break down between North America and ex North America, just to give us some help on that? You also mentioned demand in Europe a little. Perhaps you could give us a sense of the rollout you expect outside Germany and outside the U.K. in 2020, to grow the product further ex U.S.? Then, if possible, could you speak about — just Versum and what Versum contributed to EBITDA in the fourth quarter. Obviously, you've provided the breakdown for molecular — Versum, but if you could just give us that breakdown. Thank you very much.
Stefan Oschmann
executiveThanks, Richard. I think Marcus should take the Versum question.
Marcus Kuhnert
executiveYes. So Richard, let me take your second question, the one about Versum. First off, as we've already mentioned on this call, we came in a bit shy on sales and EBITDA versus the guidance we had provided. The reasons are essentially twofold: on one hand, as we said, phasing effects, and on the other, market conditions weren't particularly helpful in the fourth quarter. So we were still up against a relatively tough semiconductor market. If you run the math, and if you look, let's say, at our EBITDA bridge, the portfolio piece is essentially Versum plus intermolecular. And as we also mentioned during the call, the intermolecular effect is slightly negative. So you end up with a Versum number that is a little bit, as I said, below the €80 million to €90 million we had projected. Please also note that, with Versum now closed, we won't be giving any further Versum-specific guidance going forward, just as we didn't a couple of years ago.
Stefan Oschmann
executiveRichard, regarding the Mavenclad U.S. versus ex U.S. split, policy prevents me from giving exact figures. Naturally, we anticipate expansion in both the U.S. and ex U.S. The primary growth engine outside the U.S., or for continuing penetration, will be meaningful access gains in 2020 — specifically, plus we also have the U.K. We likewise secured elimination of the MRI requirement, which rested on a favorable recommendation, and that too will fuel growth.
Marcus Kuhnert
executiveLet me add one point, Richard. You also asked about the North America share, or the share excluding the U.S. You'll recall that during the November call, a similar question came up. At that time, we said the U.S. share was in the mid-30s percentages. Because of the stronger momentum in the U.S. right now, that share has gone up by roughly 10 percentage points since then.
Operator
operatorThe following question is from Wimal Kapadia at Bernstein. You have the floor.
Wimal Kapadia
analystThank you so much for taking my questions. This is Wimal Kapadia from Bernstein. I'd like to begin with a clarification question. Regarding what you said earlier about COVID-19 having an impact on revenues and EBITDA that is similar, does that mean a 1% effect on EBITDA? Or are you suggesting that the 1% EBIT — which is a revenue impact of roughly €180 million — will be the effect on EBITDA? My second question concerns Glucophage in China. The competitors were determined not to have quality approval. So the VVP impact won't kick in during Wave 3, but I wanted to hear your thoughts on what effect that will have in the near term, and then when you believe those companies might potentially return with a quality product, so that you would see a VVP impact? And my last question is about the GSK milestone payments. I understand you can't be specific about the euro million amounts for the milestones. Could you possibly provide some context on what the next milestones will be for, in terms of the development cycle? Thank you.
Stefan Oschmann
executiveThanks, Wimal. Let me begin with where things stand on Corona. Wimal, I believe your expectation is that we keep our attention on handling this situation. Our crisis teams are working around the clock, and that demands a great deal of effort — a great deal of effort — to sustain, so that production keeps going, our employees stay safe, and our customers continue to be supplied. Put simply, we haven't devoted effort to — to really tightening things up where margin impact is concerned. What I said earlier was not that it would be comparable. The wording I used, as I recall, was that it would not be dramatically different. So please forgive us for not offering more granular detail on that. Based on the feedback I receive, quite a few people feel we have actually been fairly granular in quantifying some kind of impact from this. China, VVP. Once more, the effect of the present crisis on the Chinese industry is something we simply cannot predict. What you should keep in mind is that, contrary to what we first assumed, Glucophage was not covered by the most recent wave.
Stefan Oschmann
executiveWhether it makes it into the next wave, we can't say. Whether the API—which also means contamination with some API from other sources—has had an effect or not, we also can't say. Still, this counts as a slight positive. The GSK milestone—Marcus will comment.
Marcus Kuhnert
executiveYeah. So I’d like to go back to what Stefan mentioned just a couple of minutes ago about the expected timing — so primary data completion is expected by the end of 2021. We said we might receive the results of an interim analysis this year, but we won’t have access to any details or data. However, those results could actually trigger the milestone payment if they are good to excellent. But obviously, nothing is included in our guidance at present.
Stefan Oschmann
executiveAnd clearly, Marcus meant the whole program.
Operator
operatorGoldman Sachs is next in line with a question.
Krishna Arikatla
analystThanks for taking my questions. I just have one. Regarding Mavenclad, could you speak to how the drug has performed in Germany, please? The reason I'm asking is that it's been roughly 2 years since you launched in the country. So are you seeing patients drop off dramatically after 2 years? And are you able to compensate for them? Thank you.
Stefan Oschmann
executiveThanks. To reiterate, we don’t break out revenue by country. What we have observed is that patient adherence is approximately 90% for returns in the second year. We’re seeing a very, very favorable trend: physicians are building experience with the drug, and they’re receiving highly favorable feedback from patients regarding the treatment regimen, which we believe is extremely appealing to patients. So Mavenclad is performing well in Germany.
Analyst
analystThanks.
Operator
operatorMichael Leuchten from UBS has the next question. Go ahead, please.
Michael Leuchten
analystMichael Leuchten at UBS here. I have a few questions, please. First, I wonder whether you might add a bit more color to what you said about not providing greater granularity on how much Life Science's margin could expand over the mid-term. You've said several times that you won't repeat that 20 to 30 basis points. Why be so specific about that? What is changing? Second, thank you for your remarks about the crisis teams and the effort needed to run the business. Is your workforce in Korea working right now? Or have they been sent home to work? And third, on your slides, you do mention safety run in trials that are ongoing. Is that the same as before? Or has that changed? Have you seen any safety sight that requires additional safety work in trials outside lung cancer? Thank you.
Stefan Oschmann
executiveNow, starting with the margin improvement in Life Science. The team in our Life Science business is performing extremely well. For a number of years now, we've been growing faster than the market. We're a margin leader, and that margin is still going up. We're very proud of our Life Science teams, but even they can't perform miracles. And we want to be fully clear and transparent with you: looking ahead, we shouldn't count on the same kind of margin expansion that has occurred over the last couple of years. Gene therapy and CAR-T offer exciting growth opportunities. There are plenty of areas where investment is needed. And we assume we're nearing a somewhat optimal balance when it comes to delivering earnings, investing, and putting money into the future. That's the context here. In Korea, our policy aligns with what the authorities recommend. I can share more specifics on Korea separately, but essentially we're applying the same principles there as we do in other countries as well. I'll come back to
Marcus Kuhnert
executiveMichael, I’ll address the workforce question. Our workforce came back after the Chinese New Year break, both on the production side and on the customer interface side. So far, we’ve had no disruptions on our end. So that’s working perfectly. Of course, we did accommodate specific needs for working from home wherever applicable, and we’re allowing for special commute situations. All of that has been handled quite diligently. But overall, there have been no disruptions on our side.
Stefan Oschmann
executiveNow, regarding the safety run component within the program — this is a routine step. There is nothing adverse implied here. The term safety run shouldn't be taken to suggest any safety issues. A safety run is simply a part of the study in which a compound, or a combination of compounds, gets evaluated for tolerability and safety before efficacy is assessed, and this mainly pertains to trials that did not have a dedicated Phase I beforehand. Also, bear in mind that how a safety run is set up may differ considerably from one study to another, based on what is already known about the compound. In this particular instance, for example, both the PTC first-line studies and the Stage III studies in lung include safety run ins and are simultaneously potentially registrational. And both of them began during 2019, as planned.
Operator
operatorThe next person to ask a question is Emily Field from Barclays.
Emily Field
analystJust a couple of quick questions. First, I realize Q4 '19 saw some trend deviations for both Erbitux and Rebif. I'm wondering how long that bullishness from China might last for Erbitux, and do you still expect a low single-digit decline for it? And on Rebif, do you still expect it to decline in line with the interferon market over time? Or is this simply the interferon market's declines slowing? Also, I know you covered this in the prepared remarks, but could you walk through again the components of health care, other operating income included in your guidance for this year, just for our modeling purposes? And finally, I'm not sure whether you can comment, but media reports have indicated you might be considering strategic options for surface solutions. If there's anything further you can provide on that.
Marcus Kuhnert
executiveLet me begin with your first question about Q4 development, particularly for Rebif and Erbitux. Rebif had a fairly strong fourth quarter. And keep in mind that I think I already provided the outlook in the November call that we expect the fourth quarter for Rebif to be better than the 2019 run rate during the first 3 quarters. During the first 3 quarters, we saw an organic decline for Rebif of roughly minus 15%. Q4 was now significantly better, owed predominantly to 2 effects. The first one was a successful price increase that we executed at the end of September, or in September, of around about 5%. And secondly, there were also some onetime effects, where we were able to release provisions that we had built for rebates. Both, listed at a Rebif results in the fourth quarter, are not sustainable. So for 2020, you should rather assume a run rate of decline in the range that we have seen over the first 9 months in 2019. Moreover, we stick to our forecast that Rebif will develop in line, overall in line with the interferon market. However, we do not see a slowing down of the decline of interferon going forward.
Marcus Kuhnert
executiveRegarding Erbitux, the first 9 months were very strong, with Q4 slightly less so. I think the primary reason here is that the comparables become more challenging. We succeeded in getting onto the national reimbursement list in China at the end of 2018, and those effects are now reflected in the comps. That means growth rates moving forward will inevitably decelerate somewhat. On your second question, about health care operating income and other operating income: for 2019, we had 3 quarters of deferred income from the GSK partnership. That came to roughly EUR 90 million. We still had 4 full quarters included with private deferred income, EUR 190 million. This will disappear in 2020. Then we had 3 milestone payments for Bavencio, all in renal cell across the 3 major jurisdictions, totaling also approximately EUR 90 million. And we had a milestone payment for a sale from earlier times tied to the sale of buy €75 million. So that is, broadly speaking, the nonrecurring income in 2019. For 2020, the €190 million will go away. In its place, we would have 4 quarters of GSK income. So if we project, say, a linear ramp up, we're thinking around €120 million, €130 million, something along those lines.
Marcus Kuhnert
executiveJust bear in mind that this relates to cost incurrence as we move forward. And what we've projected is an amount of up to a double-digit million euro figure for what we call active portfolio management income, which is broadly comparable to what we've observed across the last 2 years. So that's a factor we've built into 2020. So that accounts for the comparison.
Stefan Oschmann
executiveOn your question about plans for surface solutions: we intend to revitalize that business. We run an active portfolio management process, and all of our businesses are part of it. So we’re constantly evaluating whether each business fits well with our business model or not. And I think nobody can accuse us of not being an active portfolio manager—at least those of us with a long enough memory. We sold VWR. We sold generics. We bought Sirona. We bought Millipore. We bought AC electronic materials. We sold biosimilars. We bought Sigma-Aldrich. We sold consumer health. We bought materials. We recently sold our allergy business. So I think anyone can be assured that we take this very seriously, and that we’ll be very unemotional about it. That being said, we have no plans to divest our Surface solutions business.
Operator
operatorThe following question is from Daniel Wendorff at Commerzbank.
Daniel Wendorff
analystTwo, if I may. First, a follow-up on how margins are developing in life science. Is it fair to ask how elastic margin development is relative to top line development here? In other words, assuming you keep growing the top line at 8% to 9%, could a 20 to 30 basis points margin improvement still be possible also beyond 2020 under this scenario? That would be my first question. And the second one is more of a strategic M&A question. With Thermofisher now in the process of acquiring QIAGEN basically, meaning consolidation in the industry is continuing, do you still feel comfortably positioned across all 3 different businesses within the Life Science division?
Stefan Oschmann
executiveOn margin, elasticity, and life science, we'll of course keep running efficiency programs within life science and keep improving how efficiently we operate. You've heard me mention specifically the investments we're making in future areas, namely gene therapy and cell-based therapy—cell-based therapy. That is in fact a significant factor in the context of what you asked regarding Thermo Fisher's acquisition of QIAGEN. The innovation model in the life science industry differs somewhat from that of the pharma industry, where far more M&A activity is underway, and those deals are frequently bolt-on kinds of yields, or else there are larger transactions. We are never content with where our businesses stand. We always aim to get better. Still, we don't see this move as a strategic threat to our business model.
Operator
operatorFalko Fredricks from Deutsche Bank has our next question.
Falko Fredricks
unknownI've got three questions, if I may. First, on the €20 million synergy target in performance materials for this year: did I hear correctly that it's fully included in the guidance? And how are you planning to book those synergies, and will they sit within organic expansion? Second, in performance materials and specifically in semis, what are you currently seeing regarding fab utilization among your customers? And third, in pharma, could you elaborate a little on those cost efficiency measures, and how much additional run rate potential do you see going forward?
Kai Beckmann
executiveKai here. Appreciate the question about performance materials. So the synergies—most of them, naturally, sit within the portfolio piece that's reflected in the guidance, and a smaller portion, obviously, comes from the MAX side. You'll be able to see that reflected in our figures over the next few months. So portfolio accounts for the larger share. Regarding the semiconductor utilization rate, we already observed—and I believe this was reported at the close of last year for certain customers, and at the start of this year—that in logic there's an enormous ramp-up versus the prior year when it comes to utilization. So a number of the fabs appear to already be running at capacity. That's the first really strong signal of market recovery we picked up. In memory, things are still trailing. So on the whole, we're seeing companies move nearer to the IoT over recent weeks.
Stefan Oschmann
executiveRegarding the cost situation in health care, I want to bring up 2 factors. First, we stated very clearly a while back that 2018 was an investment year for R&D spend, and that going forward we would anticipate a more balanced approach in pharma R&D, which has a significant impact on the numbers here. Beyond that, we have actually been running a stringent cost management program across the corporation. Marcus, the sector CEOs, and I have been working very hard on that. We expect that to continue having a positive effect, which is reflected in our guidance. When it comes to — so let's — let me return to pipeline management, the cost allocation. So we would strategically reallocate some of the savings that have been created to strategically important programs without, however, jeopardizing the base business.
Operator
operatorDavid Evans from Kepler, Cheuvreux has our next question.
David Evans
analystSecond, really regarding the health care pipeline. First, about Bavencio in bladder cancer, I was simply wondering whether there are any updates on when the data will be presented and filed, and so forth? And then any sign of whether you view this as potentially being a truly meaningful indication for the drug. You also mentioned a substantial rise for Bavencio sales in 2020. I'm just wondering if you might provide some color on what would be driving that rise? Is it ex U.S. growth and the uptick in renal cancer in the U.S.? Or is there any benefit at all from bladder cancer in there? Second, on the interim analysis again, just to check that I thought you said even without expansion, the study is registrational. Is that on its own or with other studies? And I understand the study has to remain blinded, but is there a plan to publicly notify the markets where the study is being expanded or not.
Stefan Oschmann
executiveI'll begin with what you asked about the strongly favorable data on the potential matter — that data is going to be shown at a major conference in mid 2020. Right now we are in discussions about the data with the appropriate regulators around the world. It's a — each — keep in mind that the design of this study is unique, and we tested it in a switch maintenance setting. What that means is chemo first, followed by the checkpoint inhibitor, rather than giving them concurrently, and it was the first immunotherapy trial to hit OS in first-line urothelial cancer. So our view is that this represents a significant development. You raised a question regarding the bintrafusp interim analysis. Yes, this is — on its own, this study is registrational. The — the third question you raised concerned Bavencio sales in 2020. So we see — clearly, we keep marketing in cell carcinoma. We keep the — we keep the RCC rollout going, and we anticipate a positive effect from these excellent cancer data, since many prescribers overlap, in fact, when you look at renal cell cancer and urothelial cancer.
David Evans
analystAll right, thanks. So I just want to confirm something: do you think some non-promoter benefit from those strong bladder cancer results might arrive as soon as this year?
Stefan Oschmann
executiveLet me stay factual here — I was discussing this earlier. What I was saying is that when it comes to prescribers, there's considerable overlap between bladder cancer and renal cell cancer.
Marcus Kuhnert
executiveAnd keep in mind, David, that late in 2019 we also got approval for renal cell cancer in Europe and in Japan. So essentially we saw 0 impact from that in 2019. And of course, we're hoping something comes through in 2020, so that will add to growth this year as well.
Stefan Oschmann
executiveAnd yes, we really can't wait for that data to be presented in 2020. That's really all I'm able to say.
Operator
operatorThe last question this afternoon is from Sachin Jain at Bank of America.
Sachin Jain
analystI have a few questions, if I may. First, on semi, could you provide a bit more detail on which indicators you're watching that give you confidence a recovery is coming? And what is your lead time — not any shift in those indicators — meaning if the macro picture changes because of COVID, how far ahead of your indicators would you see that? The second question goes back to life science margins. If I recall correctly, at the September Analyst Day you were quite outspoken that your margins led the industry and topped peers. With the new investments in gene therapy and cell-based that you mentioned, is there any chance life science margins could drift back toward the industry average? Then the last question concerns the BTK. Clearly, Phase IIb data in RA are expected soon. Could you frame how excited you are about RA and how quickly you'd be prepared to advance to a potential Phase III study if the data support it?
Kai Beckmann
executiveI'll begin with the SME question. You asked about the indicators we monitor at a macro level — naturally, on the equipment side of the business we examine wafer fab equipment, and on the materials side what we refer to as wafer are million square inch MSI, and that provides a solid macro read. However, given that this is a fairly focused market with fewer customers, the strongest indicators are really our conversations with customers and, let's say, the projects we're executing with them, which give us far better insight. Looking at all those data points we have, and as I mentioned earlier, we saw the ramp-up in logic quite early this year, and at present we already see memory recovering, which is good and gives us useful insights. That is, of course, every project gets assessed from the perspective of, well, it's a factory operating — will there be shutdowns and similar things. So those are the insights we have.
Stefan Oschmann
executiveRegarding life science margin, Sachin, I want to be very clear on that point. In my earlier comment, I was responding to a question about what to expect for internal margin expansion within life science, so to speak. What I was attempting to convey is that a natural ceiling exists there. I wasn't suggesting any margin regression whatsoever — just to make that clear. On BTK, among rheumatologists, there's not much I can say until we've communicated the data. We anticipate having data in-house during the first half of 2020 for RA and SLE. Should these data turn out positive, in those indications we will most likely proceed — we might proceed with a partner, and let's put it that way.
Sachin Jain
analystCould I return to Kai for a moment and verify how long the lead time is on those indicators in semis?
Kai Beckmann
executiveThe macro indicators are heavy, and they always tend to be the back mover. That is a fact we know once they have happened. That is why the projects give us a fairly immediate view on things. So we know when they are going to order. So there is no substantial lead time that we need to look at. Of course, the factories ramp down, and that may have a lead time that we need to understand and discuss with our customer.
Operator
operatorMy apologies — please continue.
Stefan Oschmann
executiveThanks a lot. A few final thoughts here. In our view, the fourth quarter was a really strong quarter. We're quite pleased with how that quarter performed. We're quite pleased with how every business performed in 2019. We're extremely optimistic about the year 2020, though there are limits on how well we can forecast what COVID-19's impact will be. But let me repeat once again what we stated at the Capital Markets Day. Merck is a company with steady earnings growth, with 3 attractive, highly innovative businesses that have very attractive margins. And we should — we therefore believe that to the markets that sometimes give us a — because they perceive us as being a conglomerate, which we obviously reviewed, but when the market gives us a discount. And we think that during such turbulent times, a business like ours is why we might be effective one way or the other, could actually be — could prove to be very resilient. Thank you very much.
Operator
operatorThanks, everyone, for being here. That wraps up today's call. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.